EP1019529A4 - Verfahren zur krebsbehandlung - Google Patents

Verfahren zur krebsbehandlung

Info

Publication number
EP1019529A4
EP1019529A4 EP98941069A EP98941069A EP1019529A4 EP 1019529 A4 EP1019529 A4 EP 1019529A4 EP 98941069 A EP98941069 A EP 98941069A EP 98941069 A EP98941069 A EP 98941069A EP 1019529 A4 EP1019529 A4 EP 1019529A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98941069A
Other languages
English (en)
French (fr)
Other versions
EP1019529A1 (de
Inventor
David C Heimbrook
Deborah Defeo-Jones
Allen I Oliff
Steven M Stirdivant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9724299.4A external-priority patent/GB9724299D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1019529A1 publication Critical patent/EP1019529A1/de
Publication of EP1019529A4 publication Critical patent/EP1019529A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98941069A 1997-08-27 1998-08-26 Verfahren zur krebsbehandlung Withdrawn EP1019529A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5710297P 1997-08-27 1997-08-27
US57102P 1997-08-27
GBGB9724299.4A GB9724299D0 (en) 1997-11-18 1997-11-18 A method of treating cancer
GB9724299 1997-11-18
PCT/US1998/017699 WO1999010525A1 (en) 1997-08-27 1998-08-26 A method of treating cancer

Publications (2)

Publication Number Publication Date
EP1019529A1 EP1019529A1 (de) 2000-07-19
EP1019529A4 true EP1019529A4 (de) 2002-09-11

Family

ID=26312616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98941069A Withdrawn EP1019529A4 (de) 1997-08-27 1998-08-26 Verfahren zur krebsbehandlung

Country Status (5)

Country Link
EP (1) EP1019529A4 (de)
JP (1) JP2001514191A (de)
AU (1) AU8921398A (de)
CA (1) CA2301880A1 (de)
WO (1) WO1999010525A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066144A2 (en) 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6939540B1 (en) 2000-07-31 2005-09-06 Cornell Research Foundation, Inc. Method of enhancing bone density

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030343A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996034113A2 (en) * 1995-04-27 1996-10-31 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
WO1997030992A1 (en) * 1996-02-26 1997-08-28 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030343A1 (en) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996034113A2 (en) * 1995-04-27 1996-10-31 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
WO1997030992A1 (en) * 1996-02-26 1997-08-28 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9910525A1 *

Also Published As

Publication number Publication date
EP1019529A1 (de) 2000-07-19
WO1999010525A1 (en) 1999-03-04
JP2001514191A (ja) 2001-09-11
CA2301880A1 (en) 1999-03-04
AU8921398A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
EP0973396A4 (de) Verfahren zur behandlung von krebs
EP1100119A4 (de) Verfahren zur plasmabearbeitung
EP0709877A4 (de) Verfahren für plasma-behandlung
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
EP0888053A4 (de) Verfahren zur behandlung von krebs und infektionskrankheiten und dafür verwendbare zusammensetzungen
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
FR2777466B1 (fr) Appareil de traitement de tumeur
EP0930091A4 (de) Methode zur abgasbehandlung
FR2663044B1 (fr) Appareil pour le traitement de surfaces.
FR2710812B1 (fr) Procédé et installation pour le traitement des semences et des bulbes.
EP1028457A4 (de) Verfahren zur plasmabehandlung
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
FR2770534B1 (fr) Procede pour enlever des graffitis
EP0761604A3 (de) Mittel für die Wasserbehandlung
FR2728895B1 (fr) Procede de preparation du difluoromethane
EP0743927A4 (de) Verbessertes verfahren zur behandlung von abwasser
FR2728142B1 (fr) Composition pour le traitement anti-germinatif de tubercules ou de bulbes ; procede de traitement
EP0672457A3 (de) Verfahren zur rückstandsfreien Abfallbehandlung.
EP0860867A4 (de) Oberflächenbehandlung für mikrobearbeitung
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
FR2768725B1 (fr) Procede de preparation du 2-chloroprop-1-ene
FR2719240B1 (fr) Procédé de traitement des suspensions huileuses.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000327

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000327;LT PAYMENT 20000327;LV PAYMENT 20000327;MK PAYMENT 20000327;RO PAYMENT 20000327;SI PAYMENT 20000327

A4 Supplementary search report drawn up and despatched

Effective date: 20020731

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030527